Scientists / Our Scientists

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page or call 1-877-436-3683.

  • A link to this page has been copied to your clipboard.

    https://www.gene.com/scientists/our-scientists/teemu-junttila

    Paste this link in an email to share.

    Ok
Scientists / Our Scientists
Teemu Junttila - Principal Scientist, Translational Oncology

Teemu Junttila

Principal Scientist, Translational Oncology

15
Years at Genentech
19
Publications

I joined Genentech in 2006, initially as a post doctoral fellow. I transitioned to leading a research team in 2010. What attracted me to Genentech the most, and still does, is the unique opportunity to be involved in a drug discovery project from concept all the way to clinical development. The immediate proximity between discovery scientists and clinical scientists allows for unique synergy - my research can be rapidly guided by clinical signals without delay, which I find extremely motivating and rewarding. My role is to lead large molecule biology research that translates new antibody engineering technologies into oncology therapeutics. Currently, we are focusing on bispecific antibodies that can be used to redirect T cells to attack tumors.

Featured Publication

Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing.

Cancer Cell. 2017 Mar 13;31(3):383-395.

Li J, Stagg NJ, Johnston J, Harris MJ, Menzies SA, DiCara D, Clark V, Hristopoulos M, Cook R, Slaga D, Nakamura R, McCarty L, Sukumaran S, Luis E, Ye Z, Wu TD, Sumiyoshi T, Danilenko D, Lee GY, Totpal K, Ellerman D, Hötzel I, James JR, Junttila TT.

View Abstract

Publications
Education
© 2021 Genentech, Inc. All rights reserved. This site is intended for US residents only.